Saturday 17 October 2026
Export ELAB’s income statement to Excel — free account
PMGC Holdings Inc.
ELAB Healthcare Biotechnology
PMGC Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $590,100.00, down 65.5% from fiscal 2023. In the quarter to June 2026, revenue grew 147.7%, EPS grew 98.4% and free cash flow fell 45.0%, each against the same quarter a year earlier.
2.77
0.27
−8.88%
Follow ELAB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.01 |
+8 more quarters Free account |
P/S ratio |
2.29 | 1.48 | 0.41 | 1.37 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.97) | (0.89) | (0.41) | (1.87) | |
P/B ratio |
0.35 | 0.21 | 0.09 | 0.33 | |
Price to Tangible BV |
0.77 | 0.38 | 0.18 | 0.56 | |
EV/Sales |
(4.89) | (6.70) | (3.01) | (2.55) | |
EV/EBITDA |
1.12 | 1.38 | 0.76 | 0.85 | |
EV/Operating CF |
1.54 | 1.59 | 0.87 | 0.84 | |
EV/FCF |
1.40 | 1.44 | 0.81 | 0.79 | |
Quick Ratio |
1.27 | 1.38 | 1.60 | 1.62 | |
Current Ratio |
1.36 | 1.45 | 1.74 | 1.79 | |
Net Debt/EBITDA |
5.26 | 4.66 | 2.45 | 3.93 | |
Debt/Assets |
0.75% | 1.38% | 0.66% | 0.00% | |
Debt/Equity |
0.02 | 0.03 | 0.01 | 0.00 | |
Asset Turnover |
0.11 | 0.10 | 0.16 | 0.16 | |
Operating CF/Net income |
0.68 | 0.60 | 0.59 | 0.57 | |
Capex/Depreciation |
0.09 | (2.09) | (5.80) | (2.71) | |
Interest Coverage |
(6.57) | (7.03) | (10.73) | (126.37) | |
Research and Development Expense of Revenue |
23.74% | 6.91% | 10.82% | 5.25% | |
Selling, General and Administrative Expense of Revenue |
124.80% | 207.64% | 329.43% | 276.67% | |
Intangible Assets out of Total Assets |
0.25 | 0.22 | 0.30 | 0.23 | |
Share Based Compensation of Revenue |
13.36% | 1.20% | 3.49% | 4.62% | |
Graham Net Nets |
0.17 | 1.11 | 2.59 | 1.19 | |
Graham Number |
0.00 | 0.00 | 0.00 | 130,189.37 | |
Earnings Yield |
(8,800.30%) | (2,398.46%) | (1,070.55%) | 15,375.05% | |
Free Cash Flow Yield |
(152.40%) | (314.29%) | (898.40%) | (235.80%) | |
Revenue per Share |
2.68 | 15.33 | 152.05 | 129.95 | |
Operating CF per Share |
(4.08) | (66.96) | (875.00) | (677.36) | |
Capex per Share |
0.06 | (8.16) | (173.35) | (43.45) | |
Free Cash Flow per Share |
(4.02) | (75.12) | (1,048.35) | (720.82) | |
Cash per Share |
38.54 | 339.05 | 2,987.20 | 3,865.73 | |
Shareholders Equity per Share |
34.33 | 283.29 | 3,918.70 | 3,859.41 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
34.33 | 283.29 | 3,918.70 | 3,859.41 | |
Free Cash Flow |
(1.96) | (3.34) | (2.10) | (1.59) | |
Working Capital |
5.50 | 5.09 | 2.93 | 4.31 | |
Capital Expenditures |
0.03 | (0.36) | (0.35) | (0.10) | |
Net Current Asset Value |
1.01 | 2.96 | 1.84 | 3.33 | |
EV/EBIT |
1.07 | 1.34 | 0.75 | 0.85 | |
Capex to Sales |
(0.02) | 0.53 | 1.14 | 0.33 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.34 | 0.30 | 0.17 | 0.20 | |
Average Payables |
0.77 | 0.52 | 0.59 | 0.89 | |
Average Inventory |
0.96 | 0.62 | 0.52 | 0.31 | |
Average Assets |
22.97 | 17.46 | 10.93 | 13.07 | |
Average Common Equity |
12.89 | 10.37 | 7.25 | 8.52 |
Columns are period end dates